ID   LK63/A3KD
AC   CVCL_ZV65
SY   LK63 EphA3-knockdown; LK63-EphA3 knockdown
DR   GEO; GSM2373802
DR   GEO; GSM2373803
DR   Wikidata; Q98126922
RX   PubMed=27922598;
CC   Knockout cell: Method=shRNA knockdown; HGNC; HGNC:3387; EPHA3.
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7986 ! LK63 [Melbourne]
SX   Sex unspecified
AG   Children
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 10-04-25; Version: 6
//
RX   PubMed=27922598; DOI=10.1038/leu.2016.371;
RA   Charmsaz S., Al-Ejeh F., Yeadon T.M., Miller K.J., Smith F.M.,
RA   Stringer B.W., Moore A.S., Lee F.-T., Cooper L.T., Stylianou C.,
RA   Yarranton G.T., Woronicz J., Scott A.M., Lackmann M., Boyd A.W.;
RT   "EphA3 as a target for antibody immunotherapy in acute lymphoblastic
RT   leukemia.";
RL   Leukemia 31:1779-1787(2017).
//